Zai Lab logo .png
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
June 16, 2021 07:30 ET | Zai Lab Limited
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
Zai Lab logo .png
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
June 01, 2021 07:30 ET | Zai Lab Limited
Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and TaiwanMirati to receive an upfront payment of $65 million, up to approximately $273...
Zai Lab logo .png
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 28, 2021 07:30 ET | Zai Lab Limited
TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX:...
Zai Lab logo .png
Zai Lab Announces Upcoming Presentations in June Investor Conferences
May 25, 2021 07:30 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that...
Zai Lab logo .png
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
May 24, 2021 09:21 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the...
Zai Lab logo .png
Zai Lab Announces First Quarter 2021 Financial Results
May 10, 2021 07:32 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results...
Zai Lab logo .png
Zai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021
April 26, 2021 07:30 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, April 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will...
Zai Lab logo .png
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
April 23, 2021 10:49 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, April 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today...
Zai Lab logo .png
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
April 20, 2021 19:40 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today...
Zai Lab logo .png
Zai Lab Announces Proposed Public Offering of American Depositary Shares
April 19, 2021 16:05 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today...